Clinical Trials Logo

Lung Squamous Cell Carcinoma clinical trials

View clinical trials related to Lung Squamous Cell Carcinoma.

Filter by:

NCT ID: NCT06436040 Recruiting - Clinical trials for Lung Squamous Cell Carcinoma

Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

Start date: January 24, 2024
Phase:
Study type: Observational

To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy

NCT ID: NCT06255197 Recruiting - Lung Cancer Clinical Trials

Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers

Start date: November 4, 2019
Phase:
Study type: Observational

This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this study aims to harness the potential of real-world big data to (1) describe characteristics and treatment patterns and their evolving trends; (2) discover features associated with overall survival; and (3) address recently-emerging clinical questions.

NCT ID: NCT05782764 Recruiting - Clinical trials for Lung Squamous Cell Carcinoma

A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).

NCT ID: NCT05778253 Recruiting - Clinical trials for Lung Squamous Cell Carcinoma

The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC

Start date: March 23, 2023
Phase:
Study type: Observational

The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.

NCT ID: NCT05024266 Recruiting - Immunotherapy Clinical Trials

Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma

TACT
Start date: August 1, 2021
Phase: Phase 2
Study type: Interventional

Tislelizumab combined with chemotherapy has shown good efficacy and safety in clinical studies of lung adenocarcinoma (RATIONALE 304) and lung squamous cell carcinoma (RATIONALE 307), thus has been approved as the first-line therapy for advanced non-small cell lung cancer (NSCLC) in China. However, there is no data in the field of neoadjuvant therapy for NSCLC. This single-arm, single-center phase II clinical study is designed to evaluate the efficacy, safety and major pathological response (MPR) of Tislelizumab combined with chemotherapy as neoadjuvant therapy in patients with stage IIIA-IIIB (N2) lung squamous cell carcinoma. Biomarkers correlated with efficacy outcomes will also be explored.

NCT ID: NCT05010330 Recruiting - Lung Cancer Clinical Trials

Identify Prognostic Biomarkers of Lung Cancer

Start date: July 1, 2020
Phase:
Study type: Observational

Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.

NCT ID: NCT04802876 Recruiting - Clinical trials for Hepatocellular Carcinoma

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors

ACROPOLI
Start date: April 12, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.

NCT ID: NCT04267913 Withdrawn - Clinical trials for Stage IV Lung Cancer AJCC v8

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Start date: September 5, 2020
Phase: Phase 2
Study type: Interventional

This phase II LUNG-MAP treatment trial studies how well sapanisertib and docetaxel work for the treatment for squamous cell lung cancer that is stage IV or has come back (recurrent). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sapanisertib and docetaxel may work better in treating patients with squamous cell lung cancer compared to standard chemotherapy.

NCT ID: NCT04152018 Active, not recruiting - Ovarian Cancer Clinical Trials

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Start date: November 13, 2019
Phase: Phase 1
Study type: Interventional

Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This study contains two parts, single agent dose escalation (Part 1A), dose finding of PF 06940434 in combination with anti-PD-1 (Part 1B) and dose expansion (Part 2). Part 2 Dose Combination Expansion will enroll participants into 3 cohorts at doses determined from Part 1B in order to further evaluate the safety of PF-06940434 in combination with anti-PD-1.

NCT ID: NCT04132102 Recruiting - Clinical trials for Lung Squamous Cell Carcinoma

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

Start date: November 27, 2018
Phase: Phase 4
Study type: Interventional

This is an open-label, sing-arm, single site, phase IV clinical study. The main objective is to evaluate the efficacy of afatinib in LSQC patients with EGFR sensitive mutation, and to explore the clinical factors which might be predictive for the effectiveness in LSQC.